Showing results (81-90 of 199) with videos related to

Sort By:
Pageof 20
Haematologica|August 26, 2003
Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantationMiguel A Díaz, Julián Sevilla, Javier de la Rubia, et al.
Annals of Hematology|February 12, 2009
Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatmentAlberto Alvarez-Larrán, Julio del Río-Garma, Misericòrdia Pujol, et al.
Transplantation and Cellular Therapy|June 9, 2025
Redefining Engraftment Syndrome After Post-Transplant Cyclophosphamide Allogeneic Hematopoietic Cell Transplantation: A Novel Classification and Impact on OutcomesRafael Benavente, Juan Montoro, Aitana Balaguer-Roselló, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myelomaMaría Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2009
Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemiaJaime Sanz, Miguel A Sanz, Silvana Saavedra, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 12, 2017
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosisBonaventura Casanova, Isidro Jarque, Francisco Gascón, et al.
Transplantation and Cellular Therapy|May 10, 2026
Secondary Malignancies after Hematopoietic Stem Cell TransplantationPedro Asensi Cantó, Miguel Mansilla-Polo, Juan Montoro, et al.
Blood|April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMAndrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2022
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label studyMaría-Victoria Mateos, Miguel-Teodoro Hernández, Carlos Salvador, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
Pageof 20